Conference Coverage

Antiepileptic drug outcomes have remained flat for 3 decades


 

EXPERT ANALYSIS FROM IEC 2019

Whither are neurostimulatory device therapies headed?

Dr. Brodie was quick to admit that as a pharmacologic researcher, device modalities including vagus nerve stimulation, responsive neurostimulation, and deep brain stimulation are outside his area of expertise. But he’s been following developments in the field with interest.

“These device therapies have shown efficacy in short-term randomized trials, but very few patients attain long-term seizure freedom. I think these are largely palliative techniques. I gave up on these techniques a long time ago because I felt it was a very costly way of reducing seizures by a relatively small margin, and really we need to go a little bit further than that. But I know there’s a lot of work going on at the moment,” he said.

Dr. Brodie reported serving on the scientific advisory boards of more than a half dozen pharmaceutical companies.

Pages

Recommended Reading

Induced seizures as effective as spontaneous in identifying epileptic generator
MDedge Neurology
Gabapentinoids associated with suicidal behavior, overdose
MDedge Neurology
Lack of CBD oil regulations hearkens back to patent medicines
MDedge Neurology
Anticholinergic drugs linked to dementia in older populations
MDedge Neurology
Patients with focal epilepsy have progressive cortical thinning
MDedge Neurology
Alzheimer’s disease raises risk for recurrent seizures
MDedge Neurology
Cutaneous reaction to AEDs? Think autoimmune epilepsy
MDedge Neurology
Noninvasive EEG may speed diagnosis of West syndrome
MDedge Neurology
Statins crush early seizure risk poststroke
MDedge Neurology
Liberalized low–glycemic-index diet effective for seizure reduction
MDedge Neurology